drugset
drugset / Trial / NCT00881738

To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions

NCT00881738 ↗

Phase 1 Completed 32 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability of Clarithromycin 250 mg tablets under fasting conditions.

Timeline

Start
2002-06
Primary completion
2002-06
Completion
2002-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule 250 mg —

Indications

No indication recorded.